+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Cancer Tubulin Inhibitors Market & Clinical Trial Insight 2024

  • PDF Icon

    Clinical Trials

  • 225 Pages
  • February 2018
  • Region: Global
  • Kuick Research
  • ID: 4458874

“Global Cancer Tubulin Inhibitors Market & Clinical Trial Insight 2024” report gives comprehensive insight on the clinical and non-clinical parameters related to the emergence and development of role of tubulin inhibitors in the cancer therapy.  Report highlights the clinical development of more than 70 cancer tubulin inhibitors in pipeline and shares in-depth dosage/price analysis of 10 cancer tubulin inhibitors commercially available in the market.

“Global Cancer Tubulin Inhibitors Market & Clinical Trial Insight 2024” Report highlights:

  • Clinical Insight on 70 Tubulin Inhibitors in pipeline
  • Dosage & Price Analysis of 10 Commercialized Drugs
  • Patent Approval, Expiry Year & Market Sales Indicators
  • Patent Analysis of Key Drugs
  • Global Cancer Tubulin Inhibitors Clinical Pipeline by Company & Phase
  • Future Perspective of Cancer Tubulin Inhibitors

Cancer therapy has been one of the most extensive fields of research and development which acquires a vast portion of global therapeutic market. Development and commercialization of various advance cancer therapeutics such as targeted therapies and immunotherapies have been providing evidences of the rapid growth of cancer therapy market. However such chemotherapies follow a complex mechanism of action as they intend to target the DNA of the cancer cell and fail to achieve that target completely leading to generation of several adverse effects and drug resistances. Thus, such cancer therapies are said to be less effective in cancer treatment and thus leading to unmet medical needs of the patients.

Recently developed Tubulin Inhibitors have proven to be one of the unique cancer therapeutics as they directly target the tubulin fibers which are involved in division of cancer cells overcoming the major limitation of other cancer therapeutics. Target of Tubulin Inhibitors are microtubules which are a component of a cell involved in a process of cell division called mitosis. During mitosis cell divides to form identical cells by separating chromosomes and this separation of chromosomes is carried out by microtubules. Thus, Tubulin inhibitors stop cancer cells division which further increases the feasibility to remove cancer.

Tubulin inhibitors are widely used due to their superiority against other cancer therapeutics such as better efficacy, negligible adverse effects and high specificity. Therefore, a wide range of investors and market players are attracted towards this class of anti-cancer drugs and are actively supporting the production and commercialization of tubulin inhibitors for cancer therapy. 

Tubulin Inhibitors already have a great presence in the global cancer therapy market with more than 10 marketed products. Sales data of these tubulin inhibitors clearly indicates that they are widely accepted for clinical use. Moreover, the revenues generated by the major market players of tubulin inhibitors have further encouraged other large as well as small scale pharmaceutical companies to enhance research, development and commercialization of more tubulin inhibitors.

Global Tubulin inhibitor market is set to grow exponentially in coming four to five years due to the presence of a wide range of promising candidates in the later phases of clinical trials. Additionally, increase in cancer prevalence and unmet medical needs of cancer patients will increase the customer base for tubulin inhibitors and will further drive the global tubulin inhibitor market. Furthermore, after the commercial success of tubulin inhibitors in the developed countries, the tubulin inhibitor market is highly opportunistic for the developing countries as well, expanding the market globally.

Continuous and active research by the scientific community to produce unique tubulin inhibitors and acquiring better knowledge of their importance in cancer management are the major factors which have led to higher investments from both public and private sectors to encourage the development of tubulin inhibitors. Huge support for development and commercialization of tubulin inhibitors suggests global tubulin inhibitor market will grow continuously in the coming future and tubulin inhibitors are here to stay in the cancer therapy market.

Table of Contents

1. Microtubules - Moving Target in Cancer Therapy
1.1 Overview
1.2 Tubulin Inhibitors for Cancer Treatment
1.2.1 Microtubule Stabilizing Proteins
1.2.2 Microtubule Destabilizing Proteins
2. Mechanism of Action & Mechanism of Resistance of Tubulin Inhibitors
2.1 Mechanism of Action
2.2 Mechanism of Resistance to Microtubule Binding Agents
3. Microtubules & Their Role in Cellular Stress in Cancer
3.1 Tubulin Alterations in Cancer
3.1.1 Changes in Tubulin Isotype Composition
3.1.2 Tubulin Post Translational Modifications
3.1.3 Microtubule Associated Proteins (MAP)
3.2 Tubulin Cytoskeleton in Stress Response
4. Prognostic Role of Tubulin for Prediction of Cancer Aggressiveness
4.1 Non Small Cell Lung Cancer
4.2 Prostate Cancer
4.3 Breast Cancer
4.4 Colorectal Cancer
4.5 Ovarian Cancer
5. Price & Dosage Analysis of Tubulin Inhibitor Drugs
5.1 Docetaxel
5.2 Trastuzumab Emtansine
5.3 Abraxane
5.4 Brentuximab Vedotin
5.5 Cabazitaxel
6. Market Analysis of Tubulin Inhibitors
6.1 Overview
6.2 Global Sales of Tubulin Inhibitors Drugs
7. Global Cancer Tubulin Inhibitors Clinical Pipeline Overview
8. Global Cancer Tubulin Inhibitors Clinical Pipeline by Company & Phase
8.1 Research
8.2 Preclinical
8.3 Clinical
8.4 Phase-I
8.5 Phase-II
8.6 Phase-II/III
8.7 Phase-III
8.8 Preregistration
9. Marketed Cancer Tubulin Inhibitors Clinical Insight
9.1 Docetaxel (Taxotere)
9.2 Trastuzumab Emtansine (Kadcyla)
9.3 Vinflunine (Javlor)
9.4 Albumin-Bound Paclitaxel (Abraxane & Coraxane)
9.5 Cabazitaxel (Jevtana)
9.6 Brentuximab Vedotin (Adcetris)
9.7 Paclitaxel Polymeric Micelle Formulation (Cynviloq & Genexol-PM)
9.8 Paclitaxel Liposomal - Sun Pharma Advanced Research Company
9.9 Paclitaxel Liposomal (Lipusu)
9.10 Paclitaxel Nanoparticle (Nanoxel)
10. Global Cancer Tubulin Inhibitors Market Dynamics
10.1 Favorable Market Parameters
10.2 Commercialization Challenges
11. Future Perspective of Cancer Tubulin Inhibitors
12. Competitive Landscape
12.1 Abraxis Biosciences
12.2 Agensys
12.3 Amgen
12.4 Celgene
12.5 Eagle Pharmaceuticals
12.6 Endocyte
12.7 Genentech
12.8 Immunogen
12.9 Modra Pharmaceuticals
12.10 Pierre Fabre
12.11 Roche
12.12 Sanofi-Aventis
12.13 Seattle Genetics
12.14 Tocris Bioscience
List of Figures
Figure 1-1: Structure of Microtubule
Figure 1-2: Types of Tubulin Inhibitors for Cancer Treatment
Figure 3-1: Pathways for the Development of Cancer by Tubulin Alterations
Figure 3-2: Post Translational Modifications in Tubulin Structure
Figure 3-3: Structural Representation of Microtubule Associated Proteins
Figure 3-4: Tubulin Response to Cytoskeleton Stress
Figure 5-1: Docetaxel - Patent Approval & Expiry Year
Figure 5-2: Docetaxel - Available Concentrations mg/ml
Figure 5-3: Docetaxel - Average Dosage Analysis in Breast Cancer Therapy (mg/m2)
Figure 5-4: Cost of Docetaxel Drug for the Concentration of 10 mg/ml, for 2 Milliliters, 8 Milliliters & 16 Milliliters, Respectively (US$), 2017
Figure 5-5: Cost of Docetaxel Drug for the Concentration of 20 mg/ml, for 1 Milliliters, 4 Milliliters, 8 Milliliters & 10 Milliliters, Respectively (US$), 2017
Figure 5-6: Cost of Docetaxel Drug for the Concentration of 40 mg/ml, for 0.5 Milliliters, & 2 Milliliters, Respectively (US$), 2017
Figure 5-7: Docetaxel - Average Breast Cancer Treatment Cost (US$/Cycle), 2017
Figure 5-8: Docetaxel - Average Lung Cancer Therapy Cost Analysis (US$/Cycle), 2018
Figure 5-9: Trastuzumab  Emtansine - Patent Approval & Expiry Year
Figure 5-10: Trastuzumab Emtansine - Average Dosage Analysis (mg/Dose)
Figure 5-11: Available Different Concentrations of Trastuzumab Emtansine (mg)
Figure 5-12: Trastuzumab Emtansine - Price by Concentration (US$), 2017
Figure 5-13: Trastuzumab Emtansine - Vials Used in Metastatic Breast Cancer Treatment (By Number)
Figure 5-14: Trastuzumab Emtansine - Average Treatment Cost Analysis (US$), 2017
Figure 5-15: Abraxane - Patent Approval Year for Various Cancer Indications & Expiration Year
Figure 5-16: Abraxane Dosage Analysis by Indication (mg/m2)
Figure 5-17: Cost of Abraxane Intravenous Solution of 100 mg, US$
Figure 5-18: Abraxane - Cancer Treatment Cost Analysis per Cycle (US$), 2017
Figure 5-19: Brentuximab Vedotin - Patent Approval & Expiry Years in US
Figure 5-20: Brentuximab Vedotin - Patent Approval & Expiry Years in Europe
Figure 5-21: Price of Brentuximab Vedotin Drug for Per Vial of 50 mg & For 7 Cycles Treatment, (US$), 2017
Figure 5-22: US - Brenuximab Vedotin Price Analysis, (US$), 2017
Figure 5-23: US - Brenuximab Vedotin Treatment Expenditure (US$), 2014
Figure 5-24: US - Brenuximab Vedotin Treatment Cost (US$), 2017
Figure 5 25: Cabazitaxel - Price of Drug per Cycle in US$ & Patent Expiration Year
Figure 5-26: Cost of Jevtana Intravenous Solution & Per Unit Cost, US$, 2017
Figure 6-1: Global Sales of Docetaxel Drug (US$ Million), 2015 & 2016
Figure 6-2: Global - Trastuzumab Emtansine Sales Revenue, US$ Millions, 2013 & 2016
Figure 6-3: Global - Abraxane Sales US$ Million, 2014-2017*
Figure 6-4: Global - Brenuximab Vedotin Sales (US$ Million), 2014-2017
Figure 6-5: Global - Blinatumumab Half Yearly Sales (US$ Million), 2015-2017
Figure 6-6: Global - Sales of Cabazitaxel Drug, US$ million, 2015 - 2017*
Figure 7-1: Global - Cancer Tubulin Inhibitors Clinical Pipeline by Phase (%), 2017 till 2024
Figure 7-2: Global - Cancer Tubulin Inhibitors Clinical Pipeline by Phase (Number), 2017 till 2024
Figure 7-3: Global - Cancer Tubulin Inhibitors Clinical Pipeline by Phase (%), 2017 till 2024
Figure 7-4: Global - Cancer Tubulin Inhibitors Clinical Pipeline by Phase (Number), 2017 till 2024
Figure 10-1: Favorable Market Parameters for Tubulin Inhibitors Development
Figure 10-2: Challenges to the Market Growth of Tubulin Inhibitors
List of Tables
Table 3-1: Clinical Studies of Tubulin Isotype in Drug Resistance
Table 5-1: Trastuzumab Emtansine Price Analysis
Table 5-2: Efficacy Results of Brentuximab Vedotin in Hodgkin Lymphoma Patients



Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abraxis Biosciences
  • Agensys
  • Amgen
  • Celgene
  • Eagle Pharmaceuticals
  • Endocyte
  • Genentech
  • Immunogen
  • Modra Pharmaceuticals
  • Pierre Fabre
  • Roche
  • Sanofi-Aventis
  • Seattle Genetics
  • Tocris Bioscience